Cryoport Stock Forecast, Price & News

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cryoport in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Cryoport stock.
View analyst ratings for Cryoport or view top-rated stocks.

6 equities research analysts have issued 12-month price objectives for Cryoport's shares. Their CYRX stock forecasts range from $41.00 to $92.00. On average, they anticipate Cryoport's stock price to reach $61.17 in the next twelve months. This suggests a possible upside of 103.3% from the stock's current price.
View analysts' price targets for Cryoport or view top-rated stocks among Wall Street analysts.

Cryoport's stock was trading at $59.17 at the beginning of 2022. Since then, CYRX stock has decreased by 49.2% and is now trading at $30.08.
View the best growth stocks for 2022 here.

Cryoport is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Cryoport.

Cryoport, Inc. (NASDAQ:CYRX) released its earnings results on Thursday, May, 5th. The consumer goods maker reported ($0.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by $0.11. The consumer goods maker had revenue of $52.30 million for the quarter, compared to analysts' expectations of $52.86 million. Cryoport had a negative trailing twelve-month return on equity of 13.79% and a negative net margin of 128.78%. The company's quarterly revenue was down 1.9% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.13) earnings per share.
View Cryoport's earnings history.

Cryoport updated its FY 2022 earnings guidance on Monday, May, 30th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $260.00 million-$265.00 million, compared to the consensus revenue estimate of $257.32 million.

Some companies that are related to Cryoport include Perrigo (PRGO), Ionis Pharmaceuticals (IONS), Intra-Cellular Therapies (ITCI), Ascendis Pharma A/S (ASND), Alkermes (ALKS), Apellis Pharmaceuticals (APLS), Hypera (HYPMY), Evotec (EVTCY), Ultragenyx Pharmaceutical (RARE), Cerevel Therapeutics (CERE), Cytokinetics (CYTK), Mirati Therapeutics (MRTX), Turning Point Therapeutics (TPTX), Galapagos (GLPG) and Karuna Therapeutics (KRTX).
View all of CYRX's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Cryoport investors own include Gilead Sciences (GILD), Advanced Micro Devices (AMD), Micron Technology (MU), NVIDIA (NVDA), Taiwan Semiconductor Manufacturing (TSM), Amarin (AMRN), QUALCOMM (QCOM), Enterprise Products Partners (EPD), Pfizer (PFE) and Square (SQ).

Cryoport trades on the NASDAQ under the ticker symbol "CYRX."

Cryoport's stock is owned by many different institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (7.12%), Invesco Ltd. (6.54%), BlackRock Inc. (6.13%), Chevy Chase Trust Holdings Inc. (3.36%), Victory Capital Management Inc. (3.34%) and Clearbridge Investments LLC (2.45%). Company insiders that own Cryoport stock include Daniel M Hancock, Daniel M Hancock, Edward J Zecchini, Freeze Parent LP Blackstone, Jerrell Shelton, Mark W Sawicki, Michael R Egeck, Richard J Berman and Robert Stefanovich.
View institutional ownership trends for Cryoport.

CYRX stock was sold by a variety of institutional investors in the last quarter, including Handelsbanken Fonder AB, Chevy Chase Trust Holdings Inc., Granahan Investment Management LLC, Handelsinvest Investeringsforvaltning, PEAK6 Investments LLC, Redwood Investments LLC, Williams Jones Wealth Management LLC., and Bank of America Corp DE. Company insiders that have sold Cryoport company stock in the last two years include Daniel M Hancock, Edward J Zecchini, Freeze Parent LP Blackstone, Jerrell Shelton, Mark W Sawicki, Michael R Egeck, Richard J Berman, and Robert Stefanovich.
View insider buying and selling activity for Cryoport or view top insider-selling stocks.

CYRX stock was acquired by a variety of institutional investors in the last quarter, including Massachusetts Financial Services Co. MA, Invesco Ltd., Renaissance Technologies LLC, Victory Capital Management Inc., Clearbridge Investments LLC, abrdn plc, Vanguard Group Inc., and State Street Corp.
View insider buying and selling activity for Cryoport or or view top insider-buying stocks.

Shares of CYRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CYRX stock can currently be purchased for approximately $30.08.

Cryoport (NASDAQ:CYRX) has a market capitalization of $1.49 billion and generates $222.61 million in revenue each year. The consumer goods maker earns $-275.53 million in net income (profit) each year or ($6.11) on an earnings per share basis.

Cryoport employs 791 workers across the globe.

Cryoport's mailing address is 112 Westwood Place Suite 350, Brentwood TN, 37027. The official website for Cryoport is www.cryoport.com. The consumer goods maker can be reached via phone at (949) 470-2300, via email at [email protected], or via fax at 949-470-2306.